News

Net loss for the year ended December 31, 2008, was $9.13 million, or $0.38 per share, compared with a net loss of $7.28 million, or $0.31 per share,

According to Intradigm, the allowed subject matter covers a specific double-stranded small interfering RNA (siRNA) sequence that is directed against the angiogenic pathway and which possesses therapeutic potential

St Jude Medical, a medical device company, has received the FDA’s approval for its newest version of the Merlin.net Patient Care Network, an internet-based remote care system for

The company has partnered with Nobel Ilac for Turkey, PharmaSwiss for Israel and Adcock Ingram for South Africa for commercializing the product, subject to regulatory review and approval,

Net loss for the year ended December 31, 2008 was $6.08 million, or $0.07 per share, compared to a net loss of $3.45 million, or $0.04 per share,

For the 12 months ended December 31, 2008, net loss attributable to common stockholders was $81.25 million, or $3.25 per share, compared to a net loss attributable to

For the 12 months ended December 31, 2008, net loss was $62.46 million, or $2.12 per share, compared with a net loss of $31.74 million, or $1.14 per

The decrease in the net loss is mainly attributable to a decrease in the accretion in the carrying value of the convertible senior unsecured notes and interest due

Concert Pharmaceuticals, a biotechnology company, has announced positive Phase I clinical trial results of CTP-347, an investigational non-hormonal treatment for vasomotor symptoms or hot flashes. CTP-347, a novel